window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

About admin web

This author has not yet filled in any details.
So far admin web has created 7 blog entries.

Novigenix honored as Best 2024 Technology Innovation in oncology by MATWIN Board

By |2024-05-30T12:31:57+02:0029 May 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, May 29, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of 'Best 2024 Technology Innovation' in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix's groundbreaking contributions to personalized cancer care and its commitment to advancing

Revolutionizing Colorectal Cancer Screening with Novigenix Innovations

By |2024-06-17T20:38:04+02:0027 May 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by 63%

Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements

By |2024-05-24T15:24:35+02:004 April 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan consortium

Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling

By |2024-06-17T20:37:37+02:0017 January 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as

Novigenix appoints Dr. Pedro Romero as Chief Medical & Scientific Officer

By |2024-05-02T16:11:45+02:005 January 2024|News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions,  recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In

Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM

By |2024-04-22T21:46:41+02:004 October 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for

Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas

By |2024-04-22T21:53:09+02:0030 June 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND –  Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society

Go to Top